SATYEN R MEHTA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CARTERSVILLE, GA NPI 1477558880
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology GA ABBVIE INC. All categories
General Payments — all program years on this page
$5,768.28
- Category: General Payments
- Program years: PY2018–2024
- Record count: 291
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,474.89 across 68 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,474.89 | 68 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $216.48 | 8 |
| Genentech USA, Inc. | $147.55 | 10 |
| Daiichi Sankyo Inc. | $136.46 | 7 |
| PFIZER INC. | $118.64 | 6 |
| Merck Sharp & Dohme Corporation | $107.40 | 4 |
| Acerta Pharma LLC | $81.07 | 4 |
| E.R. Squibb & Sons, L.L.C. | $67.75 | 4 |
| GlaxoSmithKline, LLC. | $57.98 | 2 |
| Exelixis Inc. | $51.95 | 2 |
| Genmab U.S., Inc. | $49.39 | 2 |
| Gilead Sciences, Inc. | $47.08 | 2 |
| BeiGene USA, Inc. | $45.05 | 2 |
| Regeneron Healthcare Solutions, Inc. | $34.27 | 1 |
| Stemline Therapeutics Inc. | $29.78 | 1 |
| EISAI INC. | $28.45 | 1 |
| Acrotech Biopharma Inc. | $26.96 | 1 |
| PharmaEssentia USA Corporation | $26.16 | 1 |
| Ipsen Biopharmaceuticals, Inc | $24.79 | 1 |
| Mirati Therapeutics, Inc. | $23.68 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $23.21 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.87 | 1 |
| Astellas Pharma US Inc | $21.26 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $21.14 | 1 |
| Janssen Biotech, Inc. | $17.23 | 1 |
| Deciphera Pharmaceuticals Inc. | $17.06 | 1 |
| Alexion Pharmaceuticals, Inc. | $16.90 | 1 |
| Karyopharm Therapeutics Inc. | $15.33 | 1 |
By program year
Records — PY2024 (68)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.